{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:40:00Z","timestamp":1794879600592,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["755094"],"award-info":[{"award-number":["755094"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyotrophic lateral sclerosis (ALS) is a highly debilitating neurodegenerative condition. Despite recent advancements in understanding the molecular mechanisms underlying ALS, there have been no significant improvements in therapeutic options for ALS patients in recent years. Currently, there is no cure for ALS, and the only approved treatment in Europe is riluzole, which has been shown to slow the disease progression and prolong survival by approximately 3\u00a0months. Recently, tauroursodeoxycholic acid (TUDCA) has emerged as a promising and effective treatment for neurodegenerative diseases due to its neuroprotective activities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The ongoing TUDCA-ALS study is a double-blinded, parallel arms, placebo-controlled, randomized multicenter phase III trial with the aim to assess the efficacy and safety of TUDCA as add-on therapy to riluzole in patients with ALS. The primary outcome measure is the treatment response defined as a minimum of 20% improvement in the ALS Functional Rating Scale-Revised (ALSFRS-R) slope during the randomized treatment period (18\u00a0months) compared to the lead-in period (3\u00a0months). Randomization will be stratified by country. Primary analysis will be conducted based on the intention-to-treat principle through an unadjusted logistic regression model. Patient recruitment commenced on February 22, 2019, and was closed on December 23, 2021. The database will be locked in September 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This paper provides a comprehensive description of the statistical analysis plan in order to ensure the reproducibility of the analysis and avoid selective reporting of outcomes and data-driven analysis. Sensitivity analyses have been included in the protocol to assess the impact of intercurrent events related to the coronavirus disease 2019. By focusing on clinically meaningful and robust outcomes, this trial aims to determine whether TUDCA can be effective in slowing the disease progression in patients with ALS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03800524\">NCT03800524<\/jats:ext-link>\n                      . Registered on January 11, 2019.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07638-w","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T07:02:11Z","timestamp":1701759731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6183-0735","authenticated-orcid":false,"given":"Flavia L.","family":"Lombardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Spila Alegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lo Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Christian","family":"Ludolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Corcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard H.","family":"Van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Hardiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vanacore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Dickie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Puopolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TUDCA-ALS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tornese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoniangela","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Matteoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Lauranzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Malosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Adriana","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Chi\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Moglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolina","family":"Salamone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Spera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha Cristina","family":"Ranchicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Stipa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Frondizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lunetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Sansone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tarlarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gerardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Silani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Doretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Demirtzidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioacchino","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Trojsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Passaniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Ballestrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Dorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Weiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fromm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Wiesenfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Witzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Kettemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"M\u00fcschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Wohnrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Sarikidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Osmanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Grosskreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annekathrin","family":"R\u00f6diger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ilse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Smesny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Untucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Vidovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Wollff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Tuddenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mbombe","family":"Kazoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Madarshahian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh K.","family":"Chhetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Chaouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn A.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coliver","family":"Hanemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Couratier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Esselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Camu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"De La Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendal","family":"Lemasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Masrori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Fogarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyosi","family":"Atoyebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh N\u00ed","family":"Ob\u00e1in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"7638_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000351153","volume":"41","author":"A Chio","year":"2013","unstructured":"Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41:118\u201330. https:\/\/doi.org\/10.1159\/000351153.","journal-title":"Neuroepidemiology"},{"key":"7638_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3109\/21678421.2013.787629","volume":"14","author":"JM Mehal","year":"2013","unstructured":"Mehal JM, Holman RC, Schonberger LB, Sejvar JJ. Amyotrophic lateral sclerosis\/motor neuron disease deaths in the United States, 1999\u20132009. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:346\u201352. https:\/\/doi.org\/10.3109\/21678421.2013.787629.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"7638_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/med.21528","volume":"39","author":"MK Jaiswal","year":"2019","unstructured":"Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39:733\u201348. https:\/\/doi.org\/10.1002\/med.21528.","journal-title":"Med Res Rev"},{"issue":"5","key":"7638_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/jnnp-2021-328470","volume":"93","author":"P Tornese","year":"2022","unstructured":"Tornese P, Lalli S, Cocco A, Albanese A. Review of disease-modifying drug trials in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022;93(5):521\u20139. https:\/\/doi.org\/10.1136\/jnnp-2021-328470.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"7638_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/ene.12664","volume":"23","author":"AE Elia","year":"2016","unstructured":"Elia AE, Lalli S, Monsurr\u00f2 MR, Sagnelli A, Taiello AC, Reggiori B, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45\u201352.","journal-title":"Eur J Neurol"},{"issue":"1","key":"7638_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40035-022-00307-z.PMID:35659112","volume":"11","author":"K Khalaf","year":"2022","unstructured":"Khalaf K, Tornese P, Cocco A, Albanese A. Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Transl Neurodegener. 2022;11(1):33. https:\/\/doi.org\/10.1186\/s40035-022-00307-z.PMID:35659112. (PMCID:PMC9166453).","journal-title":"Transl Neurodegener"},{"key":"7638_CR7","unstructured":"ICH E9. Statistical principles for clinical trials-Scientific guidelines. International Conference on Harmonisation E9. https:\/\/www.ema.europa.eu\/en\/ich-e9-statistical-principles-clinical-trials-scientific-guideline. Accessed 14 Jul 2023."},{"issue":"23","key":"7638_CR8","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/jama.2017.18556","volume":"318","author":"C Gamble","year":"2017","unstructured":"Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Dor\u00e9 C, et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017;318(23):2337\u201343. https:\/\/doi.org\/10.1001\/jama.2017.18556.","journal-title":"JAMA"},{"issue":"13","key":"7638_CR9","doi-asserted-by":"publisher","first-page":"1009113","DOI":"10.3389\/fneur.2022.1009113","volume":"27","author":"A Albanese","year":"2022","unstructured":"Albanese A, Ludolph AC, McDermott CJ, Corcia P, Van Damme P, Van den Berg LH, et al. Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: the TUDCA-ALS trial protocol. Front Neurol. 2022;27(13):1009113. https:\/\/doi.org\/10.3389\/fneur.2022.1009113.","journal-title":"Front Neurol"},{"key":"7638_CR10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12913-016-1471-x","volume":"16","author":"J Whittle","year":"2016","unstructured":"Whittle J, Yamal JM, Williamson JD, Ford CE, Probstfield JL, Beard BL, et al. Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial. BMC Health Serv Res. 2016;16:236.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"7638_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med"},{"key":"7638_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293\u2013302.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"7638_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/CLEP.S153196","volume":"10","author":"RP van Eijk","year":"2018","unstructured":"van Eijk RP, Eijkemans MJ, Rizopoulos D, van den Berg LH, Nikolakopoulos S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol. 2018;10:333\u201341.","journal-title":"Clin Epidemiol"},{"issue":"7","key":"7638_CR14","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1093\/brain\/awac394","volume":"146","author":"M Benatar","year":"2023","unstructured":"Benatar M, Wuu J, Turner MR. Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal. Brain. 2023;146(7):2711\u20136. https:\/\/doi.org\/10.1093\/brain\/awac394. (PMID:36310538;PMCID:PMC10316774).","journal-title":"Brain"},{"issue":"2","key":"7638_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ana.21743","volume":"66","author":"P Kaufmann","year":"2009","unstructured":"Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66(2):235\u201344.","journal-title":"Ann Neurol"},{"issue":"1","key":"7638_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12874-019-0793-x","volume":"19","author":"L Floden","year":"2019","unstructured":"Floden L, Bell ML. Imputation strategies when a continuous outcome is to be dichotomized for responder analysis: a simulation study. BMC Med Res Methodol. 2019;19(1):161. https:\/\/doi.org\/10.1186\/s12874-019-0793-x.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"7638_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/10705510802339072","volume":"15","author":"TE Bodner","year":"2008","unstructured":"Bodner TE. What improves with increased missing data imputations? Struct Equ Model. 2008;15(4):651\u201375. https:\/\/doi.org\/10.1080\/10705510802339072.","journal-title":"Struct Equ Model"},{"issue":"4","key":"7638_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/19466315.2020.1779122","volume":"12","author":"RD Meyer","year":"2020","unstructured":"Meyer RD, Ratitch B, Wolbers M, Marchenko O, Quan H, Li D, et al. Statistical issues and recommendations for clinical trials conducted during the COVID-19 pandemic. Stat Biopharm Res. 2020;12(4):399\u2013411. https:\/\/doi.org\/10.1080\/19466315.2020.1779122.","journal-title":"Stat Biopharm Res"},{"key":"7638_CR19","unstructured":"ICH E9 (R1). ICH Harmonised Guideline Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials E9(R1). International Conference on Harmonisation, EMA\/CHMP\/ICH\/436221\/2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf. Accessed 14 Jul 2023."},{"key":"7638_CR20","unstructured":"Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials (EMA\/158330\/2020). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/points-consider-implications-coronavirus-disease-covid-19-methodological-aspects-ongoing-clinical_en-0.pdf. Accessed 14 Jul 2023."},{"issue":"7","key":"7638_CR21","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1212\/01.wnl.0000238505.22066.fc","volume":"67","author":"J Montes","year":"2006","unstructured":"Montes J, Levy G, Albert S, Kaufmann P, Buchsbaum R, Gordon PH, et al. Development and evaluation of a self-administered version of the ALSFRS-R. Neurology. 2006;67(7):1294\u20136. https:\/\/doi.org\/10.1212\/01.wnl.0000238505.22066.fc.","journal-title":"Neurology"},{"key":"7638_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3109\/17482968.2011.633268","volume":"13","author":"A Maier","year":"2012","unstructured":"Maier A, Holm T, Wicks P, Steinfurth L, Linke P, M\u00fcnch C, et al. Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial. Amyotroph Lateral Scler. 2012;13:210\u20136.","journal-title":"Amyotroph Lateral Scler"},{"key":"7638_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/jnnp-2019-321138","volume":"91","author":"LA Bakker","year":"2020","unstructured":"Bakker LA, Schr\u00f6der CD, Tan HHG, Vugts S, van Eijk RPA, van Es MA, et al. Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALS-FRS-R. J Neurol Neurosurg Psychiatry. 2020;91:75\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7638_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13063-022-06097-z","volume":"23","author":"TP Morris","year":"2022","unstructured":"Morris TP, Walker AS, Williamson EJ, White IR. Planning a method for covariate adjustment in individually randomised trials: a practical guide. Trials. 2022;23:328. https:\/\/doi.org\/10.1186\/s13063-022-06097-z.","journal-title":"Trials"},{"key":"7638_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12874-020-01089-6","volume":"20","author":"S Cro","year":"2020","unstructured":"Cro S, Morris TP, Kahan BC, Cornelius VR, Carpenter JR. A four-step strategy for handling missing outcome data in randomised trials affected by a pandemic. BMC Med Res Methodol. 2020;20:208. https:\/\/doi.org\/10.1186\/s12874-020-01089-6.","journal-title":"BMC Med Res Methodol"},{"key":"7638_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/pst.1846","volume":"17","author":"B Huang","year":"2018","unstructured":"Huang B, Kuan PF. Comparison of the restricted mean survival time with the hazard ratio in superiori-ty trials with a time-to-event end point. Pharm Stat. 2018;17:202\u20133. https:\/\/doi.org\/10.1002\/pst.1846.","journal-title":"Pharm Stat"},{"issue":"4","key":"7638_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/19466315.2020.1785543","volume":"12","author":"E Degtyarev","year":"2020","unstructured":"Degtyarev E, Rufibach K, Shentu Y, Yung G, Casey M, Englert S, et al. Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand Framework. Stat Biopharm Res. 2020;12(4):427\u201337. https:\/\/doi.org\/10.1080\/19466315.2020.1785543.","journal-title":"Stat Biopharm Res."},{"issue":"1","key":"7638_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/life13010210","volume":"13","author":"HM Lin","year":"2023","unstructured":"Lin HM, Liu STH, Levin MA, Williamson J, Bouvier NM, Aberg JA, et al. Informative censoring-a cause of bias in estimating COVID-19 mortality using hospital data. Life (Basel). 2023;13(1):210. https:\/\/doi.org\/10.3390\/life13010210.","journal-title":"Life (Basel)"},{"issue":"3","key":"7638_CR29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.0006-341x.2000.00779.x","volume":"56","author":"JM Robins","year":"2000","unstructured":"Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779\u201388. https:\/\/doi.org\/10.1111\/j.0006-341x.2000.00779.x.","journal-title":"Biometrics"},{"issue":"1\u20132","key":"7638_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3109\/17482960903093710","volume":"11","author":"C Castrillo-Viguera","year":"2010","unstructured":"Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11(1\u20132):178\u201380. https:\/\/doi.org\/10.3109\/17482960903093710.","journal-title":"Amyotroph Lateral Scler"},{"issue":"10250","key":"7638_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0140-6736(20)31787-6","volume":"396","author":"A van Dorn","year":"2020","unstructured":"van Dorn A. COVID-19 and readjusting clinical trials. Lancet. 2020;396(10250):523\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(20)31787-6.","journal-title":"Lancet"},{"key":"7638_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678421.2021.1883669","volume":"12","author":"F Esselin","year":"2021","unstructured":"Esselin F, De La Cruz E, Pageot N, Juntas-Moral\u00e8s R, Alphand\u00e9ry S, Camu W. Increased worsening of amyotrophic lateral sclerosis patients during COVID-19-related lockdown in France. Amyotroph Lateral Scler Front Degener. 2021;12:1\u20133. https:\/\/doi.org\/10.1080\/21678421.2021.1883669.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"10","key":"7638_CR33","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/brainsci11101291","volume":"11","author":"F De Marchi","year":"2021","unstructured":"De Marchi F, Gallo C, Sarnelli MF, De Marchi I, Saraceno M, Cantello R, et al. Accelerated early progression of amyotrophic lateral sclerosis over the COVID-19 Pandemic. Brain Sci. 2021;11(10):1291. https:\/\/doi.org\/10.3390\/brainsci11101291. (PMID:34679356;PMCID:PMC8534200).","journal-title":"Brain Sci"},{"issue":"4","key":"7638_CR34","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1002\/mus.27373","volume":"64","author":"MD Galea","year":"2021","unstructured":"Galea MD, Galea VP, Eberhart AC, Patwa HS, Howard I, Fournier CN, et al. Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID-19. Muscle Nerve. 2021;64(4):E18\u201320. https:\/\/doi.org\/10.1002\/mus.27373.","journal-title":"Muscle Nerve"},{"issue":"3","key":"7638_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/CND.0000000000000335","volume":"22","author":"LP Digala","year":"2021","unstructured":"Digala LP, Prasanna S, Rao P, Govindarajan R, Qureshi AI. Impact of COVID- 19 infection among hospitalized amyotrophic lateral sclerosis patients. J Clin Neuromuscul Dis. 2021;22(3):180\u20131. https:\/\/doi.org\/10.1097\/CND.0000000000000335.","journal-title":"J Clin Neuromuscul Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07638-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07638-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07638-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T07:11:06Z","timestamp":1701760266000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07638-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7638"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07638-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3182336\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]},"assertion":[{"value":"23 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TUDCA-ALS trial has been approved by all the involved national and local Ethical Committees (the full list is available in the published protocol). Informed consent was obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author AL declares participation in Advisory Boards of Roche Pharma AG, Biogen, Alector, and Amylyx. Author CJM reports consultancy with Biogen, Amylyx, and Cytokinetics. Author PV declares participation in Advisory Board meetings for Biogen, UCB, argenx, Cytokinetics, Ferrer, Muna Therapeutics, Augustine Therapeutics, Alector, Alexion, QurAlis, VectorY, and Amylyx (paid to institution) and grant from CSL Behring (E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders; paid to institution). Author OH declares participation in Advisory Boards for Accelsiors, Biogen Idec, Cytokinetics, NeuroSense Therapeutics, Neuropath Therapeutics, Novartis, Orion, Denali, and Wave Pharmaceuticals; role as principal investigator on the PRECISION ALS Project; Academic\/Industry Collaboration funded by Science Foundation Ireland; Research collaboration with Biogen, Cytokinetics, and Ionis in delivering the IMPACT ALS survey and with Cytokinetics in delivering the REVEALS study of respiratory decline in ALS; editor-in-chief of ALS and the Frontotemporal Degeneration; editorial board member of the Journal of Neurology, Neurosurgery, and Psychiatry. Author GN declares that Bruschettini S.R.L is the pharmaceutical company providing the investigational medicinal product and industrial partner of the project, in which he is an employee as medical director. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"792"}}